Cerulea Clinical Trials

Science and Research


Phase 1/2a dose escalation safety study of voy-101 in subjects with advanced non-neovascular age-related macular degeneration.


The Beyond trial is testing a new potential treatment for Geographic Atrophy (GA), the hallmark sign of advanced dry age-related macular degeneration.
The purpose of this research study is to evaluate the safety and effectiveness of the investigational drug, VOY-101, when given as a single eye (intravitreal) injection to individuals with GA. The investigational drug is a gene therapy vector. Gene therapy is a DNA sequence that is given inside your eye to instruct the cells in your retina to produce a helpful protein called Complement Factor H Truncated (CFHT). The gene therapy’s DNA sequence is delivered to the cells in the eye by a virus that is not able to make further copies of itself. It is expected that this therapy may slow the progression of GA and thereby prevent further vision loss.
As part of the study, suitable participants will be screened to determine their eligibility for the trial. If eligible, participants will be required to attend our site in East Melbourne for at least 16 visits over the 2 year duration of the trial.
For further information about this study please contact Cerulea on (03) 8630 5300 or email info@ceruleaclinicaltrials.org.au.

  • Principal Investigator
Professor Robyn Guymer AM

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.